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Abstract
The study of engineered nanomaterials for the development of technological applications, 
nanomedicine, and nano-enabled consumer products is an ever expanding discipline as is the 
concern over the impact of nanotechnology on human environmental health and safety. In this 
review we discuss the current state of understanding of nanomaterial skin interactions with a 
specific emphasis on the effects of ultra-violet radiation (UVR) skin exposure. Skin is the largest 
organ of the body and is typically exposed to UVR on a daily basis. This necessitates the need to 
understand how UVR skin exposure can influence nanomaterial skin penetration, alter 
nanomaterial systemic trafficking, toxicity, and skin immune function. We explore the unique 
dichotomy that UVR has in inducing both deleterious and therapeutic effects on skin. The subject 
matter covered in this review is broadly informative and will raise awareness of potential 
increased risks from nanomaterial skin exposure associated with specific occupational and life 
style choices. The UVR induced immunosuppressive response in skin raises intriguing questions 
that motivate future research directions in the nanotoxicology and nanomedicine fields.
Introduction
Engineered nanoscale materials (<100 nm in one dimension) made from metals, metal 
oxides, semiconductors, and carbon including polymers, exhibit unique optical, electrical, 
mechanical, biological, and physiochemical properties not present in their bulk form. These 
properties arise in part from an increased surface area to volume ratio where a greater % of 
the atoms comprising the material exist on the surface. Engineered nanomaterials (eNMs) 
are widely exploited in many technology fields (e.g. medicine, energy, automotive, military) 
promising great benefits to mankind. They are also formulated into an ever expanding 
consumer product market. The Project on Emerging Nanotechnology in 2011 listed 1317 
nanotechnology-enabled consumer products in their inventory; an increase of 521% over 
20061. Nano-enabled products use for example, carbon nanotubes to make light weight and 
high strength sporting equipment (racquets, bikes), nano-Ag to make antimicrobial textiles 
and wound care dressings, and nanoscale ZnO and TiO2 particles to formulate ultra-violet 
radiation (UVR) protective sunscreens and daily wear skin-care products2–4. Soft 
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nanomaterials made from organic materials (lipids, proteins) also have wide commercial and 
pharmaceutical importance (liposome, solid lipid nanoparticles, dendrimers)5, 6. Currently, 
the FDA does not require manufacturers to label products containing eNMs and some 
products go to market without rigorous safety testing7–9. This has created human 
environmental health and safety concerns which has spurred efforts to investigate the ability 
of eNMs to penetrate epithelial tissue barriers and to characterize their cellular 
interactions10, 11. With a significant increase in nanotechnology enabled skin-care products 
and the corresponding increase in the potential for eNMs to contact skin, either through 
intentional product use or unintended environmental or occupational exposure, a significant 
effort has been devoted to investigate nanotechnology skin safety2, 3, 12–15.
The purpose of this review is to highlight current knowledge of eNM skin interactions with a 
specific focus on the effect of UVR skin exposure, which introduces unique considerations 
when examining the larger question of eNM skin penetration. Firstly, UVR is a ubiquitous 
environmental insult that can induce defects in the skin barrier function. Secondly, people 
frequently apply eNM containing lotions (i.e. sunscreens, daily wear cosmetics) to UVR 
exposed skin. Thirdly, UVR exerts an immunosuppressive effect on skin. The latter is 
largely linked to photo-carcinogenesis16, 17. However, UVR induced immunosuppression is 
also a widely exploited therapeutic modality used by dermatologists to treat many skin 
disorders18–22. This dichotomy of UVR having both deleterious and therapeutic effects on 
skin biology heightens the need to discover how UVR may modulate eNM skin interactions. 
In the next sections we review aspects of human skin anatomy and the effects that UVR 
exposure have on skin biology, emphasizing the implications for eNM skin contact. We 
discuss what is known from current literature about the interaction eNMs with normal and 
barrier impaired skin. Fascinating findings are revealed that motivate future research 
directions in the nanotoxicology and nanomedicine fields.
Human Skin Anatomy - Implications for eNM Skin Contact
Skin is the largest organ of the body, providing key barrier functions preventing inside-out 
water loss and outside-in protection from environmental insults (e.g. microbes, particulates, 
irritants, allergens, UVR) including eNMs. Healthy human skin is divided into the epidermis 
(thickness: 50–100 μm) and the dermis (thickness: 300–3000 μm) which are separated by the 
basement membrane [Fig. 1]. Epidermis is multilayered (stratified) epithelium composed 
largely of keratinocytes23. The stratum basale is adjacent to the basement membrane and it 
contains cuboidal basal keratinocytes that have proliferative potential. The daughter cells 
produced differentiate to form the stratum spinosum layer that contains suprabasal transient 
amplifying keratinocytes. These cells further differentiate to form the stratum granulosum 
layer comprised of cells that contain a dense presence of keratohyalin granules and lamellar 
bodies. These contain the essential proteins and lipids, respectively that are needed to form 
the stratum corneum (thickness: 10–40 μm)24, 25, the outermost layer of the skin [Fig. 2A]. 
The transition from a granular cell to a corneocyte (dead keratinocyte) is characterized by 
the degradation of the nucleus, assembly of a cornified envelope, and a reorganization of the 
keratin intermediate filaments25. The keratin network in the corneocyte is held together by 
filaggrin, which is a highly charged, cationic protein that aids in the filament aggregation 
[Fig. 2B] and disulfide bonding26. The flattened corneocytes are bound by tight junctions 
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(corneodesmosomes, Fig. 2C)27 and they are surrounded by a unique lipid lamellar bilayer 
matrix [Fig. 2D]28–30. The corneodesmosomes, the tortuous path between corneocytes and 
the lipid matrix together provide the main barrier function of skin, limiting penetration of 
hydrophilic and high molecular weight compounds31 including eNMs. Corneocytes are 
continuously sloughed off and replaced by inner keratinocytes differentiating outward. The 
epidermis is continuously renewed every 4–6 weeks depending on the region of the body32. 
Hence, the normal process of epidermal turnover can potentially hinder systemic penetration 
of substances that breech the stratum corneum barrier. Given the cationic nature of the 
filaggrin-rich stratum corneum, the lipid rich intercorneocyte space, and the overall acidity 
of the stratum corneum (pH ~4–5)33, the penetration of eNMs is anticipated to depend on 
their physiochemical properties (e.g. size, charge, composition). Understanding the factors 
that affect eNM stratum corneum penetration and the cellular interactions that can occur 
within the epidermis are critically important assessing risk from eNM skin exposure and for 
tailoring nanoparticle based transdermal therapeutics.
In addition, to basal and differentiated keratinocytes there are a number of other cell types 
present in skin that could potentiate the interaction of eNM that penetrate beyond the 
stratum corneum. Melanocytes, present the epidermis, produce melanin pigment which gives 
skin its color. They are evenly distributed along the basal layer and comprise 5% to 10% of 
epidermal cells34. The difference in skin color between light and dark pigmented individuals 
is due to the activity of melanocytes in their melanin production, not the number of 
melanocytes 35. Melanocytes and keratinocytes form an epidermal unit in a 1:36 ratio36. 
Studies investigating the sensitivity of melanocytes to eNMs are lacking. Given the critical 
role that melanocytes have in protecting keratinocytes from UVR exposure and their 
potential to transform into a deadly malignant phenotype, suggests an urgent need exists to 
investigate whether eNMs can alter melanocyte function. Skin also provides innate and 
adaptive immune functions that are readied to respond to environmental insults that breech 
the stratum corneum23, 37. Langerhans cells (LCs) in the epidermis and dermal dendritic 
cells (dDCs) in the dermis are the main antigen presenting cells (APC) in the skin38–40. LCs 
comprise ~2–4% of epidermal cells41–44. CD1a positive immunocytes45 and CD207 positive 
LCs [Fig. 3] form a tight meshwork within the epidermis and have been shown to localize 
around hair follicles at high densities, suggesting a need for increased immuno-surveillance 
surrounding these appendages. ACPs pick up antigens that breech the stratum corneum and 
migrate to the lymph nodes to activate the adaptive immune system. Skin contains a high 
density of resident T cells, ~1×106/cm2 which, for the average adult is nearly twice the 
number of T cells found in circulation41. Although skin lacks organized lymphoid structures, 
keratinocytes are able to produce a diverse repertoire of cytokines that can influence APC 
and T cell function46–48. Because skin comes in contact with numerous exogenous 
substances, the main route to allergen sensitization is consequently through skin49–53. 
Currently, little is understood about how eNM skin exposure may affect skin immune cell 
function, cytokine secretion by keratinocytes, or effect allergic skin disorders.
Other prominent features in the skin are hair follicles and sebaceous glands [Fig. 4]. Recent 
studies have solidified the important role that these structures have in mediating eNM skin 
penetration54–56. The pilosebaceous unit is a complex structure consisting of the hair shaft, 
arrector pili muscle, and the sebaceous gland. The outer root sheath (ORS) of the hair 
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follicle is contiguous with and biochemically similar to the basal layer of the 
epidermis32, 57, 58. The inner layers the follicle contain hair-producing cells. Hair follicles 
are in a continuous cycle of anagen (hair growth phase), catagen (involution phase) and 
telogen (a resting phase)58, 59. Skin resident stem cells reside in a follicular niche called the 
hair bulge32, 60–62. This suggests the potential for eNMs to interact with and perhaps alter 
stem cell function if they can penetrate and accumulate in the follicle. The hair follicle 
infundibulum is the region extending from the opening at the skin surface down to the 
sebaceous gland. Because hair follicles by-pass the stratum corneum barrier and terminate in 
the dermis, where they gain access to vascular and lymphatic systems, the hair follicle 
represents an important penetration pathway (epidermal shunt) and potential reservoir for 
systemic delivery of topically applied substances including eNM54. Hair follicle parameters 
such as orifice size, density, body distribution, and racial differences have been 
investigated63. The highest infundibular volume and therefore largest follicular reservoirs 
are found on the forehead and calf regions. Whites have significantly higher follicular 
reservoirs compared to Asians and African-Americans64. Follicular density differences are 
known to contribute to racial dependences seen in transdermal drug delivery efficacy65 and 
this sets an expectation for racial differences to exist in how eNMs interact with skin. 
However, confirmatory studies have not yet been conducted nor has it been established 
whether eNM follicular accumulation and penetration levels depend on the hair cycle phase.
Effect of UVR on Skin Barrier - Implications for eNM Skin Contact
Ultra-violet solar radiation reaching the earth consists of UVA (315–400 nm), UVB (280–
315 nm) and UVC (100–280nm) components. UVC is mostly absorbed in the upper 
atmosphere whereas UVB and UVA reach earth. UVA skin exposure penetrates deep into 
the dermis whereas UVB is mainly absorbed in the epidermis66. Skin exposure to UVR 
results in a number of biological responses including DNA damage, melanogenesis, 
generation of oxidative stress, vasodilation (skin erythema) and leukocyte infiltration67. 
Excessive and/or chronic UVR skin exposure causes sunburn, photoaging, and 
photocarcinogenesis68. UVB skin exposure from solar radiation or from tanning booths 
represent major environmental, occupational, and consumer health risks69. Unexpectedly, a 
growing source of UVR exposure is from compact fluorescent light bulbs, which are gaining 
wide acceptance as they use 75% less energy than incandescent bulbs and they produce the 
same lumens70. Studies suggest that defects in the phosphor coating applied to adsorb x-rays 
permit emission of UVA and UVC at exceedingly high levels71. Solar UVB radiation is 
however, the predominant concern as it is ubiquitous and a confirmed mutagen and 
carcinogen. It is efficiently absorbed by DNA producing cyclobutane pyrimidine dimers 
(CPDs); thymine to thymine (T<>T), thymine to cytosine (T<>C), and cytosine to cytosine 
(C<>C)72. Highly mutagenic 6,4 photoproducts are also generated but at a much lower 
frequency than CPDs73. Studies indicate that UVB skin exposure can generate ~519 CPD 
lesions per 106 normal oligonucleotide per J/cm2 [Fig. 5] 72. UVB skin exposure also 
induces dramatic effects on the cohesion and mechanical integrity of corneocytes in the 
stratum corneum74 and it induces melanogenesis. Melanocytes increase production of 
melanin and package it into melanosome vesicles. These are transferred to keratinocytes and 
positioned above the nucleus to prevent DNA damage75. Melanogenesis leads to tanning 
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that becomes visible about 72 hours after exposure76. Defects in the mechanical integrity of 
the stratum corneum with the concurrent priming of keratinocytes to uptake melanosomes 
suggests the possibility for the increased ability of eNMs to penetrate into the viable 
epidermis and to be taken up by keratinocytes77.
Skin has evolved elaborate defense systems to combat the mutagenic and oxidative stress 
effects of UVR exposure. Keratinocytes immediately respond by pausing their cell cycle to 
repair DNA lesions via the nucleotide excision repair process78. However, following high or 
chronic UVR exposure keratinocytes may not be able to repair all of the DNA damage 
generated which, can lead to mutagenesis and skin tumor formation. If and how eNM may 
alter these processes has not yet been investigated. After DNA lesions are repaired, 
keratinocytes down regulate E-cadherins [Fig. 6] which are important cell-cell adhesion 
proteins79. This facilitates a UVR-induced keratinocyte hyper-proliferation response which 
thickens skin to buttress the epidermal barrier function [Fig. 7]80. Hyper-proliferation results 
however, in a disorganized stratum corneum structure where the presence of nucleated cells 
in the stratum corneum can be detected 81, 82. This coincides with a measurable inside-out 
water loss skin barrier defect. Studies in mice (Fig. 8) indicate that the transepidermal water 
loss (TEWL) value is UVB dose and time dependent83. The peak water loss value occurs 3 
to 4 days post UVB exposure and resolves in 7 to 10 days. Studies have not yet determined 
if the TEWL value is predictive of outside-in eNM stratum corneum penetration. Nor is it 
known whether epidermal thickening can hinder systemic transport of eNMs that do 
penetrate the disrupted stratum corneum or which day post UVR exposure skin is most 
susceptible to eNM penetration.
UVB induced Immunosuppression - Implications for eNM Skin Contact
UVB skin exposure is immunosuppressive which has a consequential role in skin 
photocarcinogenesis84. It is known that UVB exposure induces skin resident APCs to exit 
skin and migrate to the lymph nodes85–87. Migration initiates immediately post UVB 
exposure and the number of APC in skin remains low for 4–14 days. This phenomenon has 
long been studied using an in vivo mouse model of contact hypersensitivity (CHS)43, 88–91. 
Here, topically applied contact allergens or haptens, such as dinitroflourobenzene (DNFB) 
and oxazolone (OXA), interact with biomolecules in skin to create antigenic substances that 
induces T cell mediated sensitization. Subsequent skin exposure to the same haptan days 
later (challenge phase) induces severe skin inflammation that is quantifiable91. However, if 
during sensitization the hapten is applied to skin pre-exposed to low doses of UVB radiation, 
the CHS response after the challenge is significantly inhibited. The cellular mechanisms of 
the UVB-induced immunosuppression response are generally understood. LCs normally 
uptake UVB-damaged skin cell debris and migrate to local lymph nodes where they induce 
T regulatory cells (Tregs) against self-antigen92. This is important for the induction of 
immunologic self-tolerance and protection from developing photosensitivity disorders91–95. 
When hapten is topically applied to UVB exposed skin, LCs mediate generation of Tregs 
against the hapten. Consequently, upon challenge the mice exhibit a significantly reduced 
CHS response in an antigen-specific fashion91, 92, 96. Antigen specificity distinguishes 
UVB-Tregs from systemic drug-induced immunosuppression91. Because UVB skin 
exposure has the potential to impair skin barrier function and to induce a skin 
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immunosuppressive response, it can also potentially influence eNM skin penetration, alter 
systemic trafficking, toxicity, and skin immune function. What is known about these will be 
revealed in the next sections.
Engineered Nanomaterial Skin Interactions
Over the past 10 years increasing research has focused on the fundamental questions of 
whether or not eNMs can penetrate the stratum corneum barrier and what factors can impact 
penetration. Factors include for example, the eNM physiochemical properties (size, shape, 
composition, charge, surface energy)97–101, vehicle affects102, 103 and the skin barrier status 
(healthy, injured, or diseased)83, 97, 104–106. In surveying the literature it has become clear 
that analytical instrument detection sensitivity and sample analysis volume, combined with 
the wide ranging use of skin models, eNM types and coatings have created challenges to 
generating both qualitative and quantitative conclusions regarding eNM skin penetration107. 
Tissue histology and transmission electron microscopy (TEM) analysis are common 
methods used to investigate eNM skin penetration but these techniques suffer from 
limitations with tissue sampling and the inability to distinguish particles from intrinsic tissue 
features and background signal. Reliance on mass spectrometry techniques to track eNM 
persistence in skin, systemic transport, or organ distribution patterns limits the ability to 
determine if penetration occurred as intact particles or as dissociated ions83, 104, 108, 109. 
Some eNMs including quantum dots (QD) and ZnO nanoparticles do exhibit unique 
fluorescent and/or nonlinear optical signatures that can help distinguish penetration of intact 
particles from ions, but the detection sensitivity can be limited by tissue 
autofluorescence107, 110–114. Nonetheless, despite these complexities, progress is being 
made toward advancing our understanding of eNM skin interactions and our ability to draw 
conclusions about nanotechnology skin safety, as can be gleaned from many recent 
reviews2, 3, 12, 14, 15, 115–117.
In general, substances that contact skin have three basic mechanisms to penetrate the stratum 
corneum barrier - transcellular through corneocytes, intercellular between corneocytes, and 
penetration via skin appendages (e.g. sweat glands, the follicular infundibidum)118. The 
transcelluar route is considered to be of little importance because the corneocyte cell 
membrane (cornified envelop) is highly impermeable although this is somewhat still 
debated119, 120. From the transdermal drug delivery field it is largely accepted that 
substances ~500 Da (~2.5 nm diameter) cannot penetrate the healthy SC barrier31. Vehicles 
in which substances are applied to skin can however enhance the penetration of higher 
molecular weight substances into deep skin layers, including eNM121, 122. Penetration 
enhancers generally work by increasing intercellular fluidity of the lipid lamella in the 
stratum corneum or by extracting non-covalently bound amphiphilic lipids from the stratum 
corneum123. From existing literature it can confidently be said that the healthy skin stratum 
corneum presents a formidable barrier to outside-in eNM penetration. However, in life it is 
quite common for skin to have barrier defective regions resulting from mechanical damage 
(cuts or scrapes), UVB exposure, use of harsh soaps or cosmetic products containing certain 
ingredients (depilatory agents, sodium lauryl sulphate, alpha-hydroxy acids) or from 
dermatologic disorders. Cutaneous defects can facilitate penetration of exogenous 
substances including large protein antigens (dust mite and plant allergens) and virus 
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particles (20 to 100 nm dia.)124, 125. Studies also show that barrier defective skin is more 
susceptible to penetration of eNMs and that eNMs penetrate the stratum corneum 
intercellularly through the lipid lamellae [Fig. 9]83, 97, 105, 106, 126–129.
Until recently the follicular penetration pathway had received little attention because hair 
follicles comprise ~0.1% of the total skin area56. Recent work has however, revealed that the 
follicular infundibulum, including sebaceous glands, comprise efficient and long-term 
reservoirs suited for accumulation of eNM54, 55. The high density of antigen presenting cells 
localized around the hair follicle [Fig. 3] and the presence of stem cells in the hair bulge 
have led researchers to target the follicular pathway for vaccine and drug delivery using 
eNM100, 130–134. Efficient access to the infundibulum reservoir requires however, that the 
sebaceous deposits and other debris in the follicular orifice be cleared. Opening the follicles 
using a cyanoacrylate-tape stripping processes has been shown to enhance deeper follicular 
penetration of particles45, 132. Particle accumulation, the depth of penetration, and retention 
in the infundibulum depend on particle size and these can be further enhanced by 
mechanical massaging of skin45, 135–140. Repetitive body motions such as walking or wrist 
flexing can also stress skin in ways that could potentially enhance follicular accumulation 
and eNM skin penetration.
The ability of eNM to accumulate in hair follicles and exhibit enhanced penetration through 
barrier defective skin heightens concerns as the prevalence of common skin disorders with 
known barrier defects (e.g. atopic dermatitis, contact dermatitis, psoriasis) are on the 
rise49, 141, 142. Few studies have however, been conducted on diseased skin making it 
difficult to draw general conclusions on whether skin disorders predispose individuals to 
increased risk of eNM penetration112. Studies are also needed to determine if hyperkeratotic 
disorders (e.g. psoriasis, epidermolytic hyperkeratosis) hinder penetration due to the 
thickened epidermis or enhance penetration due to malformations in the epidermal structure 
and barrier function. Similarly, little known about the effect of eNM skin exposure on 
allergic skin disorders143, 144. Studies are needed to determine if eNMs can induce or 
exacerbate allergic contact sensitization which is a leading occupational health concern69. 
The observation that UVR exposure can induce a skin barrier defect81, 83, 103 is a unique 
concern considering the associated immunosuppressive effect. What is known about these 
will be examined in next.
Interactions of Engineered Nanomaterials with UVR Exposed Skin
Nanomaterials can contact UVR exposed skin through the intentional use of UVR protective 
lotions, nanoparticle-containing therapeutic treatments, or through unintentional exposure 
from environmental sources. By far the most important eNM to be studied in the context of 
UVR skin exposure is that of ZnO and TiO2103, 110. Other eNM types that have been 
studied on UVR exposed skin include fluorescent QDs which facilitate tissue tracking83, 105; 
polymer nanoparticles145, polymer coated platinum nanoparticles146 and iron oxide 
nanoparticles147 for improved UVR protection. The interest in nanoparticle based UVR 
protective lotions stems from the fact that many common organic UVR filters such as, 2-
ethylhexyl 4-methoxy cinnamate (OMC) and 3-benzylidene camphor (3-BC), can penetrate 
through skin and they have been detected in urine and breast milk148, 149. Organic filters can 
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also exacerbate generation of UVR-induced reactive oxygen species (ROS) in skin150. The 
purported advantage of particle-based UVR filters is that their large size would hinder 
stratum corneum penetration and skin retention (follicular reservoir effect) to improve 
photoprotection151.
Metal oxide particle filters work by reflecting, scattering and absorbing UVR. The relative 
contribution of these mechanisms depends on particle size, crystal structure, and 
wavelength152, 153. The high surface energy the TiO2 and ZnO oxides causes primary 
particles of size 5 to 20 nm to aggregate (irreversibly bound) and these can further form 
agglomerates (loosely bound aggregates). Agglomerates that exceed 1 μm efficiently scatter 
visible light and thus apply to skin as an unappealing white gritty film154. Dispersants are 
used to maintain particle aggregates in the size range of 30–150 nm which is optimal for 
UVB and UVA absorption and for producing lotions that apply clear to skin [Fig. 10]. A 
consequence of increasing the UVR absorption capacity of nanoscale metal oxides is the 
increased photogeneration of radicals and ROS which can cause DNA lesions and lipid 
peroxidation155. Generally, the anatase form of TiO2 displays higher photoactivity, ROS 
production and cytotoxicity than the rutile form which is preferred for use in UVR 
protective cosmetics155, 156. To hinder agglomeration and to help protect skin from 
contacting the potential phototoxic TiO2 and ZnO metal oxide core, the particles are usually 
coated with for example silica, aluminum hydroxide, or methicone145, 157, 158. While much 
is understood about the formulation of UVR protective cosmetics and how to control the 
photoactive properties of eNM, very little is understood quantitatively or mechanistically 
about the penetration of nanoscale TiO2 and ZnO, or other eNM through UVR exposed skin. 
This has spurred increasing efforts over the past 5 years to examine this specific question. 
Because the biological effects of UVR on skin exposure evolve over time and involve the 
immune system, the most useful data will be generated using in vivo skin models. Here we 
review what has been gleaned from use of in vivo mouse83, 159, pig103, and human skin 
models108, 109.
The impact of UVR on nanoparticle skin penetration was first investigated by DeLouise and 
coworkers using the SKH hairless mouse model159. Carboxylated (dihydrolipoic acid 
coated) QDs were topically applied to mice in a 30% glycerol vehicle immediately 
following UVR exposure (270 mJ/cm2 UVB). The mice wore Elizabethan collars to prevent 
grooming. After 8 and 24 hr, skin samples were qualitatively examined for the presence of 
QD using tissue histology, confocal microscopy, and silver enhanced TEM with EDAX 
analysis. Low levels of penetration were seen in both the non-UVR and the UVR exposed 
mice but qualitatively much higher levels of penetration were observed in the UVR exposed 
mice. TEM images suggested that QDs penetrated the stratum corneum barrier along the 
intercellular space between corneocytes [Fig. 9]. Interestingly, despite the high UVB dose 
employed, the penetration levels observed were estimated to be extremely small compared 
to the dose applied but a quantitative organ analysis study was not performed. Because 
mouse skin is much thinner than human skin and the QDs physiochemical and dispersive 
properties differ from the metal oxides formulated in UVR protective lotions, other groups 
were motivated to investigate the penetration of TiO2 and ZnO lotions applied to UVR 
exposed pig and human skin.
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Gulson and coworkers108 recruited human subject volunteers (n = 20) to investigate the 
penetration of ZnO particles through UVR exposed skin. Subjects applied an oil-water based 
sunscreen containing isotopically labeled ZnO particles (68Zn) to their backs twice a day for 
5 consecutive days. Two different sunscreen formulations were tested: a nano-formulation 
containing of particles with primary size ~19 nm and a bulk-formulation containing particles 
>100 nm. After each sunscreen application, subjects laid in the sun on their bellies for a 
minimum of 30 min. The minimum average UVB dose was estimated to be 180 mJ/cm2 per 
30 min exposure. Venous blood and urine samples were collected. Results found small 
increases in tracer 68Zn levels in the blood and urine from all subjects however, the 
overwhelming majority of applied 68Zn was not absorbed (<0.001% absorbed in blood). 
Tracer levels in the blood and urine from female subjects who received the nano-formulation 
appeared to be higher than males receiving the same treatment and higher than all subjects 
receiving the bulk-formulation. Authors conclude that small amounts of Zn from ZnO 
particles in the sunscreen could be absorbed through the skin and detected in blood and urine 
of healthy subjects exposed to sunlight. A similar conclusion was reached in a follow-up 
study using different a sunscreen formulation and a different UVB exposure109. However, 
neither study was able to distinguish if the 68Zn detected had been absorbed as particles or 
as soluble Zn ion or both. In fact, a recent study reported that ZnO in commercial sunscreens 
is dissociated to Zn ion under UVB irradiation 160. Also, the Gulson studies did not control 
for total UVB dose or sunscreen usage on other body parts, so it is unclear if sunscreen was 
applied to barrier defective skin. It is important to note that the ability to distinguish Zn ions 
from ZnO particles in skin with sufficient sensitivity to overcome skin background signal 
has recently been demonstrated using sophisticated NIR multi-photon and second harmonic 
generation microscopy techniques110, 161, 162. Studies of sunscreen applied to human skin 
with and without barrier impairment, including patients with psoriasis and atopic dermatitis 
all find little evidence that ZnO nanoparticles can penetration beyond the SC110, 112, 114, 128. 
These techniques have, however, not yet been utilized to investigate the potential for ZnO 
particles to penetrate barrier impaired skin induced by UVR exposure.
While studies on human skin are ideal, conducting human subjects research is expensive and 
limiting. Animal models are less expensive and offer improved control over UVB dose and 
topical administration. Medical literature has long recognized that pig skin is anatomically 
and physiologically the most similar to human skin163. Monteiro-Riviere and co-workers103 
used white Yorkshire pigs to investigate the effect of UVR exposure on nanoscale TiO2 and 
ZnO skin penetration. The pigs received a UVB dose of 100 to 120 mJ/cm2 that induced a 
pale red erythema. One day after UVR exposure the sunscreens were topically applied to a 
controlled area. Metal oxides particles were incorporated into oil/water (o/w) and water/oil 
(w/o) sunscreen formulations. The application area was occluded and a second sunscreen 
dose was applied on day 2. On day 3 the skin was harvested for analysis. TEM results found 
that both nanoparticle types primarily localized as large agglomerates on the skin surface. 
On UVR exposed skin TiO2 (not ZnO) particles penetrated into layers deeper of the stratum 
corneum. A similar result was observed on explant pig ears164. The superficial penetration 
observed was modulated to some extent by the nature of the topical formulation; with the 
w/o formulation permitting deeper penetration of TiO2 into stratum corneum layers. This 
finding corroborates an early study that reported microfine TiO2 penetrated deeper into 
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human skin from an oily dispersion than from an aqueous one165. The authors further 
conclude from TEM and histology analysis that UVB exposed pig skin showed slightly 
enhance penetration and that TiO2 penetrated deeper into the SC in both normal and UVB-
exposed skin compared with ZnO. However, using the more sensitive technique of time-of-
flight secondary ion mass spectrometry (TOF-SIMS), elemental Ti was detected in the 
epidermis and superficial dermis and elemental Zn also was detected in the upper epidermis. 
Again, it is not known whether the elements were absorbed as soluble ion or as particles, but 
the results emphasize the importance of considering the analytical technique detection 
sensitivity in drawing definitive conclusions about eNM skin penetration.
While tissue histology, optical and electron microscopy techniques can provide important 
insight into the localization of eNM in the skin and can yield some understanding of cellular 
penetration mechanisms, these techniques do not yield quantitative information. To more 
fully understand the extent of eNM skin penetration and the systemic translocation, the 
techniques of inductively coupled plasma mass spectrometry (ICP-MS) and atomic 
absorption spectroscopy (AAS) are often used to evaluate eNM elemental organ collection 
patterns. Guided by results of an earlier study, that found the liver and lymph nodes were the 
major collection sites of Cd following dermal injection of (CdSe/ZnS core/shell) QDs using 
ICP-MS 111, our lab quantitatively investigated the effect of UVR skin exposure on the 
penetration of QDs topically applied to mice using AAS [Fig. 11]. SHK hairless mice we 
exposed to UVR (360 mJ/cm2 UVB) and negatively charge QDs (DLHA-coated CdSe/ZnS 
core/shell) were topically applied 3 to 4 days post UVR exposure at the peak of the TEWL 
defect [Fig. 8]. After 24 hr the Cd concentration in the lymph nodes and livers of UVR 
exposed mice were quantified relative to controls (no UVR)83. Results detected a baseline 
Cd level in the livers of control mice (vehicle treatment only); the likely source of this Cd 
was from their food. Application of QDs to UVR exposed skin found a statistically 
significant increase in liver Cd but the increase as a % of the applied does was very low. The 
baseline levels (vehicle treatment only) of Cd in the lymph nodes (with and without UVR) 
were below the limit of quantification (LOQ). Application of QDs to control mice (no UVR) 
produced an unexpected result in that Cd was detected in the lymph nodes; suggesting QDs 
penetrated barrier intact skin. This result contrasted histologic and TEM analysis of tissues 
sections, but due to the limitations of sampling and detection sensitivity mentioned earlier 
and the increased sensitivity of AAS, it is plausible that QDs can penetrate mouse skin. 
Interestingly, application of QDs to UVR exposed (barrier defective) skin produced a ~45% 
lower level of Cd the lymph nodes. This result was also unexpected and suggested an effect 
of UVR on the mechanism of systemic transport of QDs to the lymph nodes and implicated 
the role of skin resident APCs. Previous work established that LCs can uptake and traffic 
polymer NPs topically applied to skin to the lymph nodes45, 166. Due to the 
immunosuppressive effect that UVR has on skin we quantified LC density before and days 
3–4 post UVR exposure83. Results found that the LC density in skin was depleted by ~80% 
at the time QDs were topically applied. Hence, the lower Cd level in UVR treated mice is 
consistent with the lesser availability of LCs to uptake and traffic QDs to the lymph node.
Based on the above, intriguing questions arise regarding the potential for eNM that contact 
UVR exposed skin to either alter or induce skin immune responses. As discussed above 
topical application of antigen to UVB exposed skin results in the generation of antigen-
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specific Treg cells. Since UVB exposure has been shown to increases slightly the skin 
penetration of eNMs and that LCs have been shown capable of up-taking eNM and 
transporting them to lymph nodes, it is curious to question whether humans can developed 
tolerance to topically applied nanoscale materials. It is also intriguing to question the affect 
that eNM may have on LC function and their ability to present antigen. These specific 
questions have not yet been investigated. However, the potential for eNMs to modulate skin 
immune function is a rapidly growing field. A few recent examples are briefly discussed 
below.
Modulating the Skin Immune Responses with Nanoparticles
Some studies have investigated the potential to develop contact dermatitis following eNM 
skin exposure and to examine how topical application of eNMs may alter symptoms of 
allergic skin disorders. One recent study reported that subcutaneous injection of different 
size TiO2 nanoparticles (15, 50, 100 nm) (not topically applied) exacerbated development of 
atopic dermatitis (AD) symptoms (ear thickening, protein expression of inflammatory 
molecules) in mice induced by mite allergen, but no effect of particle size was observed167. 
In a companion paper a similar study was done using different size polystyrene (PS) 
nanoparticles (25, 50, 100 nm)101. Results found that injected PS nanoparticles aggravated 
AD-like symptoms even without co-exposure to mite allergen. In contrast to TiO2, a size 
effect was observed with the smaller PS particles producing greater symptoms. These 
findings were corroborated by another group that injected TiO2 nanoparticles (20, 230 nm) 
prior to topical sensitization with dinitrocholorobenzene (DNCB) and results showed TiO2 
exacerbated AD symptoms in mice168. Contrasting results have also been reported where 
topical application of both PS and TiO2 nanoparticles to barrier intact skin models did not 
induce acute cutaneous irritation or exacerbate a skin sensitization response169. Topical 
application of mesoporous silica particles (100 nm spheres) also did not induce an ear 
swelling response in mice or exacerbate allergic contact dermatitis symptoms even when co-
administered with dinitrofluorobenzene (DNFB)170. The likely differences observed 
between injection and topical application is the magnitude of the eNMs in the epidermis.
The above studies reveal the importance of particle composition on exacerbating AD-like 
symptoms and suggest a potential concern if these nanoscale materials were to contact 
severely barrier impaired skin. Clearly, for eNM to exert an immunomodulatory affect they 
must be able to penetrate skin to an appreciable extent. Penetration can be modulated by 
physical means (injection or stratum corneum depletion) or perhaps by varying both the 
eNM core and surface composition. Studies with both nanoscale gold and silver particles 
suggest these metals have a greater propensity to penetrate intact skin than metal oxides. For 
example, an in vivo study showed that topical application of 200 nm Ag particles formulated 
in a nanolipid carrier o/w cream exhibited a high capacity to reduce AD-like symptoms171. 
Similarly, topical application siRNA coated gold nanoparticles (~50 nm) designed to down 
regulate epidermal growth factor receptor (EGFR) freely penetrated the mouse epidermis 
and a human skin equivalent model within hours of application172. Following a 3 week 
application protocol of the siRNA Au particles to hairless mice nearly abolished EGFR 
expression and reduced the thickness of the epidermis by almost 40%. Whether the 
differences observed in skin penetration between nanoscale metal and metal oxide particles 
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is driven by surface coating, electronic properties, or the tendency of metal oxide particles 
aggregate to large sizes that hinder skin penetration is not yet fully understood. The role that 
nanoparticle conductivity has in modulating skin biology is also poorly understood. Studies 
have shown that bimetallic nanoparticles (Cu/Zn 20 nm) applied to skin can induce a 
galvanic couple and that the electrical stimulus generated can reduced the skin inflammatory 
response to sensitizing agents173. Citrate coated Au nanoparticles were also reported to 
interfere with downstream IL-1β signaling inhibiting the production of PI3 kinases and 
proinflammatory TNF-α release in a size dependent manner with 5 nm particles, but not 20 
nm, exhibiting the greatest neutralizing effect174. Highly conducting fullerene nanoparticles 
were reported to exhibit a potent anti-oxidant free radical scavenger activity and inhibit 
allergic anaphylaxis response in vivo175. Hence, the above examples clearly illustrate the 
rich potential for developing novel immunomodulatory therapeutics for treating skin 
disorders using eNMs but the role of particle conductivity has not yet been elucidated.
Conclusions
In this review we discussed the current state of understanding of the interactions of eNMs 
with skin. We explored the unique dichotomy that UVR exposure has on skin, raising 
awareness of the challenges to developing a generalized view of eNM skin penetration and 
translocation. While barrier impaired skin is seen as more susceptible for eNM penetration, 
the biological and immunologic responses of skin to the impairment means (chemical, 
physical, disease) will be differ and thus can influence the extent and mechanisms of eNM 
skin penetration and translocation. Existing literature currently suggests that UVR skin 
exposure can slightly enhance the penetration of eNM. Significant health issues from eNM 
occupational exposures or from use of nano-enabled products have not yet emerged. 
Nonetheless, it is curious to consider if eNM immune-tolerance via UVR-Treg generation 
exists or if it tolerance to haptans can be modulated by eNM contact with UVR exposed skin 
(i.e. TiO2 and ZnO). In vivo models will be essential moving forward for examining these 
questions and elucidating the central role that eNM composition (core/coating) has on 
dictating skin interaction so that the deleterious and therapeutic benefits of eNMs can be 
minimized and maximized, respectively. A further concern with the current state of 
understanding is the limitations imposed by the models and instrumentation utilized. It is 
challenging to relate acute high dose studies to real world human exposures. Similarly, it is 
difficult to extrapolate the significance of results that find intradermal injections of eNM can 
exacerbate AD-like symptoms to realistic topical human exposure conditions. The ability to 
attain a definitive consensus on the ability of eNMs to penetrate beyond stratum corneum is 
limited by instrumentation detection sensitivity. Clearly, there is an urgent need for 
nonbiased means to amplify the detection of eNM presence in tissues107. Simple and widely 
assessable methods that can distinguish soluble ion from particle penetration are also needed 
to advance the fields of nanotoxicology and nanomedicine.
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Figure 1. Schematic of human skin structure and constituent cell types
Skin is stratified epithelial composed of the epidermis and dermis. The epidermis is mainly 
comprised of keratinocytes. Basal keratinocytes undergo terminal differentiation to form the 
stratum spinosum, stratum granulosum, and stratum corneum barrier. Stratum lucidum is an 
additional layer present under the stratum corneum in areas of thick skin like palms of the 
hands and soles of the feet. Pigment producing melanocytes and antigen presenting 
Langerhans cells are also present in the epidermis. The dermis is a layer rich in connective 
tissue and is divided into the papillary and reticular regions. The dermis contains many cell 
types including fibroblasts that make collagen and other extracellular matrix molecules that 
provide skin mechanical toughness. Adipocytes, macrophage, mast cells, plasmatoid 
dendritic cells (pDCs), CD4+ T cells, CD8+ T cells, Tregs, and natural killer T-cells also 
abundantly present in the dermis apart from other structures including pilosebaceous unit, 
sweat glands, nerves, blood and lymphatic vessels. Adapted from Nestle et al., 2009 [23].
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Figure 2. Transmission electron micrographs illustrating unique features of skin
(A) The stratum corneum (SC) is comprised of multiple layers of enucleated and elongated 
corneocytes each defined by a dense cornified envelope indicated by the black arrows. The 
cells in the stratum granulosum (SG) are distinguished by the presence of a nucleus (N) and 
a high density of keratohyalin granules (K). Adapted with permission from Madison et al., 
1998 [24] (B) Electron micrograph of a corneocyte cytosol illustrating the nanoscale 
organization of keratin intermediate filaments. The subfilamentous molecular architecture 
appears as groups of electron dense spots surrounding a central dense dot. The keratin 
filaments are ~7.8 nm wide with a center-to-center distance of ~16 nm. (Inset box scale bar 
is 10 nm. Adapted with permission from Norlen and Al-Amoundi, 2004 [25] (C) 
Corneocytes in the stratum corneum are bound by corneodesmosome tight junctions 
indicated by black arrows. Racial differences exist in the density of corneodesmosomes. 
Scale bar is 1 μm. Adapted with permission from Gunathilake et al., 2009 [27]. (D) Electron 
micrograph illustrating the lipid lamellar bilayers in the intercellular space between 
corneocytes. Adapted with permission from Warner et al., 1999 [30].
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Figure 3. Langerhans Cell localization pattern around the hair follicle
Immunofluorescent staining of human skin epidermis with anti-CD207-Alexa 488 
(Langerin) specific for Langerhans cells showing their distribution around the hair follicle 
infundibulum, scale bar=50 μm. Inset shows the base of the hair follicle, scale bar=10 μm.
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Figure 4. Schematic of the human hair follicle in late anagen phase
The bulge, outer root sheath, hair bulb and follicle papilla are responsible for hair growth.
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Figure 5. Formation of bipyrimidine photoproducts within human skin exposed to UVB 
radiation
(A) Photoproduct formation is linear with respect to the applied UVB dose (0–0.2 J/cm2). 
The results are expressed in lesions per 106 bases and are the average ± SD. (B) A similar 
distribution of bipyrimidine photoproducts is produced in human skin and in cultured 
primary keratinocytes isolated from the same donor following UVB. Reprinted with 
permission from Mouret et. al., 2006 [72].
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Figure 6. E-cadherin expression in primary mouse keratinocytes (PMK) after acute UVR 
exposure
PMKs were harvested at the times indicated post UVR (40 mJ/cm2 UVB). Unirradiated 
PMKs were included as controls. Densitometric analysis of Western data for relative E-
cadherin levels normalized to GAPDH. E-cadherin levels were significantly different from 
control at 6, 24, and 72 h (n = 3). ***, p < 0.001. Inset, a representative Western blot for E-
cadherin from one of three separate experiments. Equal loading of protein was verified by 
GAPDH staining. Reprinted with permission from Brouxhon et. al. 2007 [79].
Jatana and DeLouise Page 27
Wiley Interdiscip Rev Nanomed Nanobiotechnol. Author manuscript; available in PMC 2015 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 7. Characterization of UVR-induced epidermal injury in SKH-1 mice
Hematoxylin and eosin stain photomicrographs of normal dorsal mouse skin (N) and of skin 
24, 72, 96, or 168 h after UVR (180 mJ per cm2 UVB) irradiation. Note the epidermal 
hyperplasia (black arrow), hyperkeratosis (white arrow), and the perivascular inflammation 
(arrowheads) present 72 h after UVR irradiation. At 168 h post UVR irradiation, the 
epidermis has returned to near normal. Scale bar: 50 μm. Reprinted with permission from 
Tripp et. al., 2003 [80].
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Figure 8. The effect of UVR on SKH mouse skin barrier function as measured by transepidermal 
water loss (TEWL)
UVR exposure increases the barrier defect in a UVB dose (0 to 360 mJ/cm2 UVB) and time 
dependent manner. A statistically significant increase in TEWL is observed for all exposures 
with the peak defect ranging from days 3 to 6 post-UVR exposure. Each value is reported as 
the mean ± SEM (n=4, *p < 0.05, **p < 0.01, ***p < 0.001). Reprinted from Mortensen et. 
al., 2013 [83].
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Figure 9. TEM imaging of mouse skin sections suggesting quantum dot nanoparticles penetrate 
intercellular between corneocytes
(A) The penetration pathway through the stratum corneum is between corneocytes which is 
shown in more detail in (B) where the large dark spots are quantum dots. (C) Another skin 
section demonstrating the penetration pathway showing quantum dot present in the stratum 
granulosum. (D) A negative control (no quantum dots). Reprinted with permission from 
Mortensen et. al., 2008 [159].
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Figure 10. Dependence of UV-visible light attenuation on TiO2 nanoparticle aggregate size
With decreasing particle size UV protection shifts to shorter wavelengths. Blue line, 20 nm; 
green line, 50 nm; and red line, 100 nm. Particles with average aggregate size of ~ 50 nm 
offer high UVB attenuation and lower visible light scattering but less UVA absorption. 
Reprinted with permission from Wang and Tooley, 2011 [154].
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Figure 11. Cadmium tissue level in distal organs following 24 hr QD nanoparticle application to 
SHK mice as a function of UVR
Liver results show that QD exposure to control mice (no UVR) does not significantly 
increase Cd level. Application of QDs to UVR exposed mice did statistically increase liver 
Cd relative to controls (no UVR with or without QD). Lymph node results show that the 
background Cd level was below the limit of quantification (<LOQ) in vehicle-treated 
animals with and without UVR exposure. Unexpectedly, application of QDs to control mice 
(no UVB) produced a high Cd level in the lymph nodes suggesting QDs penetrated intact 
mouse skin. QD application to UVR exposed mice produced lower Cd level suggesting a 
UVR dependent cellular transport QD mechanism to lymph node Each value is reported as 
the mean ± SEM (n=5, *p < 0.05). Reprinted from Mortensen et al., 2013 [83].
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